Scholars Central

Conference abstractPublished 2022

Signaling COVID-19 vaccine adverse events

Authors: William DuMouchel

Oracle Health Sciences, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Statistical signal detection is a crucial tool for rapidly identifying potential risks associated with pharmaceutical products. The unprecedented environment created by the coronavirus disease 2019 (COVID- 19) pandemic for vaccine surveillance predisposes commonly applied Signal detection methodologies to a statistical issue called the masking effect, in which signals for a vaccine of interest are hidden by the presence of other reported vaccines. This masking effect may in turn limit or delay our understanding of the risks associated with new and established vaccines. Objective: The aim is to investigate the problem of masking in the context of COVID-19 vaccine signal detection, assessing its impact, extent, and root causes. Methods: Based on data underlying the Vaccine Adverse Event Reporting System, three commonly applied statistical signal detection methodologies, and a more advanced regression-based methodology, we investigate the temporal evolution of signals corresponding to live largely recognized adverse and two potentially new adverse events. Results: The results demonstrate that signals of adverse events related to COVID- 19 vaccines may be undetected or delayed due to masking when generated by methodologies currently utilized by pharmacovigilance organizations, and that a class of advanced methodologies can partially alleviate the problem. The results indicate that while masking is rare relative to all possible statistical associations, it is much more likely to in COVID-19 vaccine signaling, and that its extent, direction, impact, and roots are not static, hut rather changing in accordance with the changing nature of data. Conclusion: Masking is an addressable problem that merits careful consideration, especially in situations such as COVID-19 vaccine safety surveillance and other emergency use authorization products.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Pharmaceutical Sciences & Emerging Drugs.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutical Sciences & Emerging Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “William DuMouchel”